Are you Dr. Jost?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 3 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
825 Eastlake Ave E
Seattle, WA 98109Phone+1 206-288-6956Fax+1 206-288-1119
Summary
- Dr. Edgar Jost, MD is a hematologist in Seattle, Washington.
Awards, Honors, & Recognition
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia Start of enrollment: 2011 Aug 01
Publications & Presentations
PubMed
- 1 citationsImpact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine.Helena Bresser, Claudia Schmoor, Olga Grishina, Dietmar Pfeifer, Johanna Thomas
European Journal of Haematology. 2025-02-01 - Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leu...Christoph Röllig, Björn Steffen, Christoph Schliemann, Jan-Henrik Mikesch, Nael Alakel
Journal of Clinical Oncology. 2025-01-01 - Validation of the Revised 2022 European LeukemiaNet Risk Stratification in Adult Patients with Acute Myeloid Leukemia.Leo Ruhnke, Marius Bill, Sven Zukunft, Jan-Niklas Eckardt, Silvia Schäfer
Blood Advances. 2024-11-06
Authored Content
- Single Versus Double Induction with “7+3” Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double TrialDecember 2022
